Brevan Howard Capital Management’s Altimmune ALT Stock Holding History

Brevan Howard Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$398K	Buy	130,781 +52,378	+67%	+$156K	﹤0.01%	1554
2026 Q1	$241K	Sell	78,403 -35,725	-31%	-$152K	﹤0.01%	1785
2025 Q4	$412K	Sell	114,128 -108,814	-49%	-$474K	﹤0.01%	1203
2025 Q3	$840K	Buy	222,942 +89,733	+67%	+$346K	﹤0.01%	984
2025 Q2	$516K	Buy	133,209 +89,405	+204%	+$484K	﹤0.01%	1344
2025 Q1	$219K	Buy	43,804 +29,773	+212%	+$189K	﹤0.01%	953
2024 Q4	$101K	Buy	+14,031	New	+$107K	﹤0.01%	966
2024 Q3	–	Sell	-32,454	Closed	-$216K	–	1117
2024 Q2	$216K	Buy	+32,454	New	+$239K	﹤0.01%	862

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's ALT Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Altimmune (ALT) stake by 67% in Q2 2026, buying an estimated $156K and bringing the position to 130,781 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

Brevan Howard Capital Management first reported a position in ALT in Q2 2024 and has held it in 8 quarters since. The position peaked at $840K in Q3 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Brevan Howard Capital Management held 130,781 shares of Altimmune worth $398K as of Q2 2026.
Brevan Howard Capital Management bought 52,378 Altimmune shares in Q2 2026, an estimated $156K.
Altimmune made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1554 holding.
Brevan Howard Capital Management first reported a position in Altimmune in Q2 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's Altimmune position peaked at $840K in Q3 2025.
210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.